A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Genentech, Inc.
KaliVir Immunotherapeutics
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Exelixis
Immatics US, Inc.
Fate Therapeutics
Hoffmann-La Roche
Fate Therapeutics
The Netherlands Cancer Institute